State Key Laboratory of Cancer Biology & Institute of Digestive Diseases, Xijing Hospital, the Fourth Military Medical University, 17 Changle Western Road, Xi'an, Shaanxi Province 710032, PR China.
Biochem Cell Biol. 2012 Dec;90(6):701-8. doi: 10.1139/o2012-028. Epub 2012 Sep 20.
Survivin has been demonstrated to be an excellent target for immunotherapy in several types of cancer, but little is known of the efficacy of survivin with gastric adenocarcinoma. In this study, a simple method was performed, and relatively high efficacy was shown upon inducing survivin-derived peptide-specific cytotoxic T lymphocytes (CTL) from peripheral blood mononuclear cells of healthy donors. The induced CTLs exhibited specific lysisagainstHLA-A2 matched tumor cells in vitro, and similar results were demonstrated in primary cell cultures isolated from patients with gastric adenocarcinoma. Up to 30% of randomly selected patients could potentially benefit from immunotherapy targeting survivin. These results suggested that this survivin epitope peptide could be a promising vaccine candidate for immunotherapy for patients with gastric adenocarcinoma.
Survivin 已被证明是多种癌症免疫治疗的优秀靶点，但对于 survivin 与胃腺癌的疗效知之甚少。在这项研究中，我们采用了一种简单的方法，从健康供者的外周血单个核细胞中诱导出 survivin 衍生肽特异性细胞毒性 T 淋巴细胞（CTL），显示出相对较高的疗效。诱导的 CTL 在体外对 HLA-A2 匹配的肿瘤细胞具有特异性溶解作用，在从胃腺癌患者分离的原代细胞培养物中也得到了类似的结果。多达 30%的随机选择的患者可能从针对 survivin 的免疫治疗中获益。这些结果表明，这种 survivin 表位肽可能是胃腺癌患者免疫治疗的一种有前途的候选疫苗。
